So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

Healthcare generates massive volumes of data daily – from electronic health records and insurance claims to genomic research ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Medical research charities LifeArc and Genetics Alliance UK have issued a call to the government to topple obstacles impeding ...

President Donald Trump took time out from the 4th July celebrations in the US to sign his One Big, Beautiful Bill Act (OBBBA) ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format ...

Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...

The pressure to execute a flawless drug or therapy launch has never been greater and continues to lay the foundation for long-term product success. A best-in-class introduction can shape ...

Explore the future of cancer care with a focus on earlier interventions and advancements in oncology care at ASCO 2025. Learn how we are building a stronger future in cancer care.